MedTrace Logo

Fast-Acting Insulin Aspart and Insulin Pump Settings

NCT04620967 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-02-16

No results posted yet for this study

Summary

To clarify the role of fast-acting insulin aspart (Fiasp) in insulin pump-treated type 1 diabetes more research is needed.

The aim of this study is twofold:

1. to compare the effects of Fiasp and Iasp in adults with type 1 diabetes who are using insulin pump and CGM and who are attending a diabetes out-patient clinic with extensive expertise in insulin pump and CGM therapy.
2. to determine differences in insulin pump settings when insulin pumps are optimally adjusted to each of the two insulin types.

Conditions

Interventions

DRUG

Insulin aspart

Insulin aspart (Iasp) in insulin pump

DRUG

Fast-acting insulin aspart

Fast-acting insulin aspart (Fiasp) in insulin pump

Sponsors & Collaborators

  • Kirsten Nørgaard

    lead OTHER

Principal Investigators

  • Kirsten Nørgaard, MD DMSc · Steno Diabetes Center Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04620967 on ClinicalTrials.gov